ESC 365 - Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles

ESC Premium Access

Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles

Session: Cancer and cardiotoxicity: from bench to bedside

Topic: Cardiotoxicity of drugs

Speaker: Doctor R. Wurm (Vienna, AT)

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Doctor Raphael Wurm

Medical University of Vienna, Vienna (Austria)

0 follower

6 more presentations in this session

Enhanced-autophagy by exenatide mitigates doxorubicin-induced cardiotoxicity in vitro and in vivo

Speaker: Miss H. Cho (Seoul, KR)

TCTP down-regulation induced cardiac cell death through Bnip3 may be a pivotal mechanism of Doxorubicin-induced heart failure

Speaker: Ms W. Cai (Guangzhou, CN)

CCAAT/enhancer binding protein delta contributes to an earlier phase of pro-inflammatory response in doxorubicin related cardiomyopathy

Speaker: Professor P. Liu (Tainan, TW)

Cardioprotective effect of taurine against doxorubicin cardiotoxicity in rats: echocardiographic and histologic study

Speaker: Doctor V. Baris (Gaziantep, TR)

Protective effect of clusterin on doxorubicin induced myocardial damage

Speaker: Associate Professor J. Lee (Goyang, KR)

Access the full session

Cancer and cardiotoxicity: from bench to bedside

Speakers: Doctor R. Wurm, Miss H. Cho, Ms W. Cai, Professor P. Liu, Doctor V. Baris...

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources